Differential effects of estrogen and estrogen receptor antagonist, ICI 182 780, on the expression of calbindin-D9k in rat pituitary prolactinoma GH₃ cells

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8498-505. eCollection 2014.

Abstract

Objective: To detect the effects of 17β-estradiol (E2) on the expression of calbindin-D9k (CaBP-9k) in pituitary GH3 cells, and to determine the antagonistic effect of a selective estrogen receptor (ER) antagonist (ICI 182 780) on CaBP-9k expression.

Methods: A rat pituitary prolactinoma cell line (GH3 cells) was used in an in vitro model. The localization of CaBP-9k in GH3 cells was observed by immunofluorescence. GH3 cells were cultured with the addition of E2 medium for 24 hours. The levels of CaBP-9k mRNA and protein expression in different groups were analyzed by RT-PCR and Western blot analysis. The ER antagonist, ICI 182 780, was added to GH3 cells before E2 (10(-8) M) at a concentration of 10(-6) M to investigate the regulation of an ER-mediated pathway on CaBP-9k expression.

Results: E2 had a stimulatory effect on CaBP-9k expression of GH3 cells in a dose-dependent manner; the level of CaBP-9k expression was higher when treated with a higher concentration of E2. ICI 182 780 suppressed the stimulatory effect of E2 on CaBP-9k expression in GH3 cells. The level of CaBP-9k expression was significantly reduced by co-administration of E2 with ICI 182 780 in GH3 cells. The immunoprecipitation results confirmed that CaBP-9k interacts directly with ERα, and E2 increases the interaction between CaBP-9k and ERα.

Conclusion: Estrogen induces CaBP-9k expression via an ERα-mediated pathway and CaBP-9k directly combines with ERα, suggesting that CaBP-9k is involved in the biological effects mediated by an ER pathway in GH3 cells.

Keywords: CaBP-9k; GH3 cells; ICI 182 780; estrogen; estrogen receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Cell Line, Tumor
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology*
  • Estrogen Receptor Antagonists / pharmacology*
  • Fluorescent Antibody Technique
  • Fulvestrant
  • Immunoprecipitation
  • Pituitary Neoplasms / metabolism*
  • Prolactinoma / metabolism*
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction
  • S100 Calcium Binding Protein G / biosynthesis*

Substances

  • Estrogen Receptor Antagonists
  • S100 Calcium Binding Protein G
  • Fulvestrant
  • Estradiol